Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 873

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 4
Chunk 873
---
 expenses 
     9,636,333  
     600,192 
  
    Related party travel costs 
     370,500  
     1,767,550 
  
    Research
    and development expenses 
     2,235,341  
     1,574,306 
  
    Total
    operating costs 
     12,242,174  
     3,942,048 

    Interest income 
     48,000  
     - 
  
    Interest expense 
     (4,338,542) 
     (1,643,049)
  
    Loss
    on extinguishment of debt 
     -  
     (7,486,767)
  
    Net
    loss 
    $(16,532,716) 
    $(13,071,864)
  
    Basic
    and diluted loss per share 
    $0.56  
    $0.48 
  
    Basic weighted average common stock shares
    outstanding 
     29,539,219  
     27,304,724 

The
accompanying notes to the financial statements are an integral part of these statements.

F-4

Telomir
Pharmaceuticals, Inc.

Statements of Changes in stockholders’
EQUITY (DEFICIT)

    Shares  
    Amount  
     Capital  
    Deficit  
     (Deficit) 

    Common Stock  
    Additional
                                                                                Paid-In  
    Accumulated  
    Total Stockholders’
                                                                                Equity 

    Shares  
    Amount  
     Capital  
    Deficit  
     (Deficit) 

    Balances, January 1, 2023 
     26,829,269  
    $              -  
    $55,000  
    $(992,278) 
    $(937,278)
  
    Issuance of common stock, net 
     268,025  
     -  
     910,000  
     -  
     910,000 
  
    Debt conversion to common stock 
     1,512,478  
     -  
     10,587,346  
     -  
     10,587,346 
  
    Shares added for fractional shares pursuant to reverse stock split 
     42